COMPANY PROFILE

Asgard Therapeutics

Explore full profile

Spin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming

Lund Municipality, SwedenFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Asgard Therapeutics

Asgard Therapeutics is a Swedish biotech startup focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Founded as a spin-off from Lund University, the company is pioneering gene therapy approaches, with its flagship program, AT108, designed to trigger immune responses by leveraging the biological properties of professional antigen-presenting cells. This method aims to simplify the logistics and manufacturing challenges associated with traditional cell-based therapies, making it a more accessible "off-the-shelf" solution.

Read full description

Asgard Therapeutics primarily serves the healthcare and pharmaceutical sectors, targeting patients and medical professionals in need of advanced cancer treatments. The company operates in the highly specialized biotech market, which is characterized by rapid innovation and significant investment in research and development.

The business model of Asgard Therapeutics revolves around the development and commercialization of its proprietary gene therapy solutions. The company generates revenue through various channels, including grants, venture capital investments, and potential future sales of its therapies. Notably, it has received support from prominent entities such as the Bio Innovation Institute and the Boehringer Ingelheim Venture Fund, which invest in groundbreaking therapeutic-focused biotechnology companies.

In summary, Asgard Therapeutics is at the forefront of cancer immunotherapy innovation, leveraging cutting-edge gene therapy techniques to create more effective and accessible treatments. The company’s strategic partnerships and funding support underscore its potential to make significant advancements in patient care.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Lund Municipality, Sweden
Employees: 28
Open positions: 1
Dealroom signal: 71.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Genetics and genomics, Spinout, Sustainable Development Goals, EIC, Biotech and Pharma, Nordic Rising Star 2022, Hard Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Mar 2024	$33M	$132M	Novo Holdings · Boehringer Ingelheim Venture Fund · Industrifonden · Johnson & Johnson Innovation	↗
SEED✓Equity / VC	Nov 2021	$6.6M	$26M	Novo Holdings · Novo Seeds · Industrifonden · Boehringer Ingelheim Venture Fund	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Asgard Therapeutics website traffic

Latest recorded traffic for Asgard Therapeutics is 5.1K monthly website visits, up 4.1% over the last three months. Asgard Therapeutics's team grew 3.7% over the past year.

Latest monthly visits5.1K 3-month web change+4.1% 1-year team growth+3.7%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SESea4UsSea4Us is a biopharmaceutical startup specializing in discovering and developing new drugs, leveraging expertise in ion channels and marine biology	Vila do Bispo, Portugal	Operational	26	$6.2M	$23M
IPIndex PharmaceuticalsDeveloping drugs to treat inflammatory bowel disease that can help patients return to a normal life	Solna kommun, Sweden	Operational
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
ILiLoFAI and photonics platform for personalized drug discovery.	London, United Kingdom	Operational
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational
LBLeukos BiotechNew treatments for Acute Myeloid Leukaemia and other haematological malignancies	Barcelona, Spain	Operational
OGOryzon GenomicsDevelops diagnostic and therapeutic tools	Cornellà de Llobregat, Spain	Operational